| Established
in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company
focused on the development and commercialization of drug-products
utilizing an innovative active transdermal drug delivery technology.
Our current proprietary drug-product development programs include
ViaDor-hPTH (1-34), a transdermal hPTH (1-34) product to treat osteoporosis, undergoing
Phase 2B clinical trials, which is developed in collaboration with Eli
Lilly, ViaDor-GLP1 agonist for the treatment of type II diabetes that has completed Phase 1b clinical study; and the ViaDor-Calcitonin that has completed a Phase 1 clinical trial.
TransPharma’s drug-product development activities
utilize our well-proven
RF-MicroChannel
Technology. Our RF-MicroChannel technology enables the
creation of an array of microscopic pores through the very outer skin
surface, allowing the delivery of therapeutic doses of a wide portfolio
of drugs, including biologics, our main area of focus. TransPharma’s
implementation of the RF-MicroChannel Technology is the
ViaDorTM
delivery system. Intended for home use, the ViaDor delivery system
consists of a reusable, handheld, low-cost device and a disposable patch containing a
drug.
TransPharma’s goal is to develop multiple
drug-products through
strategic
partnerships with leading pharmaceutical companies and
through independent product development. We believe that combining
partnered and proprietary product development ensures capitalizing of
both the promise of our technology and our growing capabilities.
|
